The string of megadeals announced in the first half of 2024 reflect a growing confidence among US dealmakers. But can the bull run be sustained?
Megadeals were firmly on the agenda in H1 as more stable inflation and...more
9/30/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
Global Dealmaking ,
Investment ,
Investors ,
Lenders ,
Mergers ,
Regulatory Agenda ,
Sellers
Global M&A activity continued to make slow progress in 2023, with stubbornly high interest rates and stringent financing conditions stifling market confidence. Nearly US$3.2 trillion of M&A deals were announced last year—a...more
2/16/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Competition ,
EU ,
Federal Trade Commission (FTC) ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Private Equity ,
Sellers ,
Technology
Ongoing uncertainty hampers dealmaking in second quarter of the year, but mining megadeals and the race for clean energy offer a ray of hope.
Global dealmakers had a lot to contend with in the second quarter of this year....more
8/15/2023
/ Acquisitions ,
Buyers ,
EU ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Private Equity Firms ,
Private Equity Funds ,
Sellers
Against the odds, dealmakers put in a solid performance in 2022, but this year has seen a slow start as buyers in the US M&A market clamor for much needed regulatory clarity -
Global M&A markets gave both optimists and...more
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
Following on from two robust first quarters, global M&A activity succumbed to prolonged market uncertainty in the third quarter. A total of 5,163 deals worth a total of US$731.3 billion changed hands during the quarter...more
While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year -
Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more
4/8/2022
/ Acquisitions ,
Activision ,
Banking Sector ,
Canada ,
Coronavirus/COVID-19 ,
Gaming ,
Global Dealmaking ,
Global Market ,
Investment ,
Investors ,
Mergers ,
Real Estate Market ,
Software ,
Technology ,
Video Games
Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals.
Nevertheless,...more
2/18/2022
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Domestic Dealmaking ,
Energy Sector ,
Financial Services Industry ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Retail Market ,
Technology Sector
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Healthy deal activity has returned to the leisure and retail sectors—areas of the economy that were among the worst affected by the pandemic.
Together, the leisure and retail sectors saw M&A value reach US$41.7 billion...more